MedTrace Logo

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

NCT06508827 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2025-07-09

No results posted yet for this study

Summary

Anemia is a common complication among cancer patients and is negatively associated with overall prognosis and therapeutic outcomes. The purpose of this study is to see if giving a dose of iron prior to any standard of care chemotherapy treatment will affect the cells that are believed to make treating melanoma harder, making melanoma more responsive to the standard of care immunotherapy.

Conditions

Interventions

DRUG

Iron dextran 1000 mg IV

Iron dextran 1000 mg IV will be administered once, about 7 days prior to standard of care treatment.

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Principal Investigators

  • Mateusz Oprychal, MD, PhD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06508827 on ClinicalTrials.gov